Tiziana Life Sciences is a buy due to its platform optionality and upcoming catalysts that outweigh its dilution risk and ...

Alector Inc. (NASDAQ: ALEC) is one of the best stocks under $3 to invest in. On October 21, Alector announced the topline ...

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an update. Cynata Therapeutics Limited is poised for a significant period with upcoming ...

PHOENIX -- A first-in-class oral miR-124 enhancer significantly improved clinical remission and endoscopic outcomes for ...

"ArkBio commences Phase II study of AK0610 for RSV prevention" was originally created and published by Clinical Trials Arena, ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...

A phase 2 clinical trial published in the Journal of Alzheimer’s Disease suggests that low-dose THC-CBD extract may improve ...

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

During IDWeek 2025 in Atlanta, Georgia, Loren G. Miller, MD, MPH, investigator at The Lundquist Institute for Biomedical ...